Apalutamide Approval Paves Way for Further Advances in Nonmetastatic CRPC

March 7, 2018 – The space of nonmetastatic castration-resistant prostate cancer (CRPC) is beginning to evolve with recent advances highlighted by the FDA-approval of apalutamide. The FDA based its decision on findings from the phase III SPARTAN trial, in which the median metastasis-free survival (MFS) was 40.5 months in the apalutamide arm versus 16.2 months in the placebo arm (HR, 0.28; 95% CI, 0.23-0.35; P <.0001). Similarly, in the phase III PROSPER ... (leggi tutto)